[Correction of thrombocyte-vascular hemostasis in metabolic syndrome].

The purpose of the study was to evaluate the therapeutic effects of lovastatin and allicor on thrombocyte-vascular hemostasis in patients suffering from arterial hypertension (AH) with metabolic syndrome (MS). Twenty-two patients were administered lovastatin in a dose of 20 mg before sleep; 23 patients received allicor in a dose of two tablets or 150 mg twice a day. The therapy lasted one month in both groups. The dynamics of the following variables was evaluated: anthropometric parameters, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, the antioxidative protectability of the lipid part of blood and thrombocytes, thrombocyte aggregation and their intravascular activity, and vascular hemostasis indices. The results were processed using Student coefficient, as well as system and correlation analysis. The study shows that lovastatin and, to a less degree, allicor, has a hypolipidemic effect, as well as a positive effect on peroxidation syndrome in patients suffering from AH with MS, optimizing thrombocyte-vascular hemostasis to the same degree. As a cheaper drug, allicor may be used widely to prevent thrombosis in patients with AH with MS. In order to lessen body mass in such patients, lovastatin and allicor should be applied together with non-drug means.

[Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin]. / Sostoianie trombotsitarnogo gemostaza u bol'nykh arterial'noi gipertoniei s metabolicheskim sindromom i ego korrektsiia lovastatinom.

The objective of the study was to evaluate the efficiency of lovastatin correction of dyslipidemia and impaired intravascular platelet activity (IPA) in patients with arterial hypertension (AH) concurrent with metabolic syndrome (MS). Eighteen patients were given lovastatin for a month. The time course of changes in anthropometric parameters, blood lipid spectrum, plasma and lipid peroxidation, antioxidative protectiveness of the liquid blood part and platelets, and IPA were assessed. The results were processed by Student's test and correlation analysis. Lovastin was ascertained to correct dyslipoproteinemia and peroxidation syndrome and to optimize the intrathrombocytic mechanisms responsible for their function regulation in patients with AH + MS. Lovastatin inhibits in vivo increased platelet activity. These effects may be stabilized during its use. Body weight loss and diminished insulin resistance in patients with AH concurrent MS require long use of lovastatin along with low-calorie diet and exercises.

[Radiation activation of angiotensin-converting enzyme during low-dose irradiation]. / Radiatsionnaia aktivatsiia angiotenzin-prevrashchaiushchego fermenta pri malykh dozakh oblucheniia.

Radiation activation of angiotensin-converting enzyme (respect to Cbz-Phe-His-Leu as substrate) was obtained at the gamma (137Cs, t(irr) = 10s-2h, D approximately 3 Gy)- and X (plasma foces source, t(irr) = 10(-9)s, Cu-filter, D approximately 2 x 10(-5) Gy)-irradiation. The inactivation of the horseradish peroxidase at the same X-irradiation dose (2 x 10(-5) Gy) took place. Based on the experimental data and on the mathematical model proposed by us we made a conclusion that the special points exist on the dose response curves. Besides, the deduction that an activation is a common process at radiation changes of the different enzymes follows from our model. The activation of tobacco peroxidase (in presence of Ca(2+)-cations and without them) and of recombinant horseradish peroxidase (in presence of H2O2) by gamma-irradiation was really observed (respect to guaiacol as substrate).